Form 4 Moderna, Inc. For: Feb 12 Filed by: Klinger Shannon Thyme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Barclays Downgrades Moderna (MRNA) to Equalweight
February 18, 2025 5:13 AM ESTBarclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).
The analyst comments "Key takeaways. Following MRNA pre-announcement (see note), 4Q24 financial updates were largely incremental, except disclosure of norovirus Ph3 NOVA-1 (NCT06592794) clinical hold... More
